-- ============================================================================
-- SURGERY 3 MCQ BATCH 28: Hepatobiliary Disorders (Questions 1621-1680)
-- Topic: Liver Tumors, Liver Surgery, Portal Hypertension, Bile Duct Injuries
-- ============================================================================

INSERT INTO questions (topic_id, category_id, question_text, option_a, option_b, option_c, option_d, option_e, correct_option, explanation, difficulty, cognitive_level) VALUES

-- Liver Anatomy and Tumors (1-25)
('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'The Couinaud classification divides the liver into:',
'Two lobes only', 'Eight functionally independent segments based on portal vein, hepatic vein, and bile duct distribution', 'Four lobes', 'Three segments', 'Ten segments',
'B', 'Couinaud classification: liver divided into 8 functionally independent segments (I-VIII), each with own portal triad (portal vein, hepatic artery, bile duct) and hepatic venous drainage. Anatomical lobes: right (V-VIII), left (II-IV), caudate (I). Segments II, III = left lateral sector. Segment IV = left medial sector. Segments V, VIII = anterior right sector. Segments VI, VII = posterior right sector. Allows targeted resections preserving function. Reference: Couinaud C. Le Foie. 1957.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'The most common benign liver tumor is:',
'Focal nodular hyperplasia', 'Hemangioma (cavernous hemangioma)', 'Adenoma', 'Cyst', 'Lipoma',
'B', 'Hepatic hemangioma: most common benign liver tumor (5-20% autopsy incidence). Cavernous type most common (blood-filled cavities). Usually asymptomatic, discovered incidentally. Large (>5cm) may cause pain, consumptive coagulopathy (Kasabach-Merritt). CT: peripheral nodular enhancement, centripetal fill-in. MRI: T2 hyperintense ("lightbulb sign"). Treatment: observation (most), surgery if symptomatic or giant. Reference: Bioulac-Sage P. J Hepatol. 2010.',
'easy', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Imaging characteristics of hepatic hemangioma include:',
'Central enhancement', 'Peripheral nodular enhancement with progressive centripetal fill-in ("fill-in" pattern)', 'Washout on delayed phase', 'Hypodense throughout', 'No enhancement',
'B', 'Hemangioma imaging: CT/MRI - peripheral nodular enhancement on arterial phase, progressive centripetal (toward center) fill-in on portal/delayed phases. May be complete or incomplete fill-in (large lesions). MRI: very T2 hyperintense ("lightbulb bright"). US: hyperechoic, well-defined. No washout. These features distinguish from HCC and metastases. Reference: Vilgrain V. Radiographics. 2000.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Focal nodular hyperplasia (FNH) is:',
'Malignant', 'A benign hepatocellular lesion, typically with central scar, that rarely requires treatment', 'Pre-malignant', 'Always requires surgery', 'Caused by oral contraceptives',
'B', 'FNH: second most common benign liver tumor. Benign hepatocellular lesion, hyperplastic response to abnormal arterial blood supply. Characteristic: central stellate scar with radiating fibrous septa. Demographics: young women (90%), not caused by OCPs (unlike adenoma). Imaging: central scar, arterial enhancement, near-isodense on delayed phase. Treatment: observation (rarely grows, no malignant potential, no hemorrhage risk). Surgery only if symptomatic or uncertain diagnosis. Reference: Bioulac-Sage P. J Hepatol. 2010.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Hepatic adenoma (HCA) is associated with:',
'No risk factors', 'Oral contraceptive use, anabolic steroids, obesity, and metabolic syndrome', 'Smoking only', 'Alcohol only', 'Exercise',
'B', 'Hepatic adenoma risk factors: (1) Oral contraceptives (most important, dose-dependent, estrogen-related), (2) Anabolic steroids, (3) Obesity/metabolic syndrome, (4) Glycogen storage diseases (type I, III). Classification: HNF1α-inactivated (35-40%), inflammatory (40-50%), β-catenin-activated (10-15%, malignancy risk), unclassified. Complications: hemorrhage, malignant transformation (β-catenin subtype). Management: stop OCPs, resect if >5cm, male, β-catenin mutated, or symptomatic. Reference: Nault JC. Hepatology. 2017.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Indications for surgical resection of hepatic adenoma include:',
'All adenomas', 'Size >5cm, male gender, β-catenin mutation, or symptomatic/hemorrhagic lesions', 'Size <1cm', 'Asymptomatic female with 2cm lesion', 'Only if multiple',
'B', 'Hepatic adenoma resection indications: (1) Size >5cm (hemorrhage, malignancy risk increases with size), (2) Male gender (higher malignancy risk), (3) β-catenin mutation (malignancy risk 20-40%), (4) Symptomatic (pain), (5) Hemorrhage, (6) Growing despite OCP cessation. Small adenomas in women: OCP discontinuation, observation with imaging. Subtype classification guides management. Biopsy if subtype unknown and affects management. Reference: European Association Study of Liver. J Hepatol. 2016.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Hepatocellular carcinoma (HCC) most commonly arises in:',
'Normal liver', 'Cirrhotic liver (80-90% of cases)', 'Young patients', 'Without risk factors', 'Acute hepatitis',
'B', 'HCC: arises in cirrhotic liver in 80-90% of cases. Cirrhosis (any etiology) major risk factor. Risk factors: hepatitis B/C, alcohol, NAFLD/NASH (rising), aflatoxin exposure, hemochromatosis, autoimmune hepatitis, PBC. Surveillance: high-risk patients with US ± AFP every 6 months. HCC can occur in non-cirrhotic HBV. Reference: European Association Study of Liver. J Hepatol. 2018.',
'easy', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'The most important imaging characteristic suggesting HCC is:',
'Hypodensity throughout', 'Arterial phase hyperenhancement with washout on portal venous/delayed phase', 'Ring enhancement', 'No enhancement', 'Peripheral enhancement',
'B', 'HCC imaging diagnosis (LI-RADS): (1) Arterial phase hyperenhancement (APHE) - tumor derives blood supply from hepatic artery, (2) "Washout" - becomes hypodense on portal venous or delayed phase (tumor venous drainage, unlike background liver). Other features: enhancing capsule, threshold growth. These features allow non-invasive diagnosis of HCC in cirrhotic liver without biopsy. CT or MRI with contrast. Reference: Chernyak V. Hepatology. 2018.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Alpha-fetoprotein (AFP) in HCC diagnosis:',
'Is always elevated', 'Is elevated in 50-70% of HCC cases but may be normal; useful for screening and monitoring', 'Is 100% specific', 'Should not be measured', 'Is diagnostic alone',
'B', 'AFP: glycoprotein, elevated in HCC but not specific. Sensitivity 60-70%, elevated in only 50-70% of HCC. Elevations also in: pregnancy, teratoma, acute/chronic hepatitis. Used for: (1) Surveillance (combined with US), (2) Prognosis (higher levels worse), (3) Monitoring treatment response. AFP >400 ng/mL suggestive of HCC but diagnostic criteria based on imaging. Normal AFP does not exclude HCC. Reference: Marrero JA. Hepatology. 2009.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Barcelona Clinic Liver Cancer (BCLC) staging system for HCC incorporates:',
'Only tumor size', 'Tumor characteristics (size, number, vascular invasion), liver function (Child-Pugh), and performance status', 'Only AFP level', 'Only patient age', 'Histology only',
'B', 'BCLC staging: standard for HCC staging and treatment allocation. Incorporates: (1) Tumor burden (size, number, vascular invasion, extrahepatic spread), (2) Liver function (Child-Pugh score), (3) Performance status (ECOG). Stages: 0 (very early), A (early) - curative treatments (resection, transplant, ablation), B (intermediate) - TACE, C (advanced) - systemic therapy, D (terminal) - best supportive care. Reference: Llovet JM. Lancet Oncol. 2003.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Curative treatments for HCC include:',
'Chemotherapy only', 'Surgical resection, liver transplantation, and ablation (RFA/MWA)', 'Radiation only', 'TACE only', 'Observation',
'B', 'Curative HCC treatments: (1) Surgical resection - early stage, preserved liver function (Child A), adequate FLR. (2) Liver transplantation - within Milan criteria (single ≤5cm or 2-3 ≤3cm, no vascular invasion, no metastases), cures HCC and underlying cirrhosis. (3) Ablation (radiofrequency RFA, microwave MWA, cryoablation) - small tumors (<3cm), high local control. 5-year survival 50-70% for curative treatments. Reference: European Association Study of Liver. J Hepatol. 2018.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Milan criteria for liver transplantation in HCC:',
'Any tumor size', 'Single tumor ≤5 cm or 2-3 tumors each ≤3 cm, no macrovascular invasion, no extrahepatic disease', 'All HCC regardless of size', 'Only if AFP <10', 'Metastatic disease allowed',
'B', 'Milan criteria (gold standard for HCC transplant selection): (1) Single tumor ≤5cm, OR (2) 2-3 tumors each ≤3cm, AND (3) No macrovascular invasion, AND (4) No extrahepatic disease. Within Milan: 5-year survival 70-75%, recurrence <10%. Outside Milan ("downstaging"): locoregional therapy to meet criteria, then transplant evaluation. UCSF criteria slightly expanded. Eliminates competing cause of death (cirrhosis). Reference: Mazzaferro V. N Engl J Med. 1996.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Transarterial chemoembolization (TACE) for HCC:',
'Is curative', 'Is a palliative therapy for intermediate-stage HCC, delivering chemotherapy and embolic particles via hepatic artery', 'Cannot be repeated', 'Is first-line for all HCC', 'Only for metastatic disease',
'B', 'TACE: locoregional therapy. Selective catheterization of hepatic artery branch feeding tumor → deliver chemotherapy (doxorubicin, cisplatin) + embolic particles (lipiodol, beads). Exploits HCC arterial blood supply. Indications: intermediate-stage HCC (BCLC B) - multinodular, preserved liver function, no vascular invasion/metastases. Palliative (prolongs survival), can be repeated. Contraindications: decompensated cirrhosis, main portal vein thrombosis. Complications: post-embolization syndrome, liver failure. Reference: Lencioni R. Radiology. 2012.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Systemic therapy for advanced HCC includes:',
'No options available', 'Tyrosine kinase inhibitors (sorafenib, lenvatinib) and immune checkpoint inhibitors (atezolizumab-bevacizumab)', 'Standard chemotherapy', 'Antibiotics', 'Steroids only',
'B', 'Advanced HCC systemic therapy: (1) First-line: atezolizumab + bevacizumab (IMbrave150 trial, current standard - superior to sorafenib), or lenvatinib, or sorafenib. (2) Second-line: regorafenib, cabozantinib, ramucirumab (AFP ≥400). TKIs target VEGF, PDGFR, RAF. Immunotherapy: PD-L1 inhibitor + VEGF inhibitor. Traditional chemotherapy not effective in HCC. Modest survival benefit but improved over BSC. Reference: Finn RS. N Engl J Med. 2020.',
'hard', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Fibrolamellar hepatocellular carcinoma differs from typical HCC in that:',
'It occurs in cirrhotic liver', 'It typically occurs in young adults without cirrhosis, with better prognosis', 'It is more common', 'It has worse prognosis', 'It never requires surgery',
'B', 'Fibrolamellar HCC: distinct variant. Epidemiology: young adults (10-35 years), equal gender distribution, NON-cirrhotic liver. Histology: large polygonal cells, abundant eosinophilic cytoplasm, lamellar fibrosis, central scar. Imaging: large mass with central scar (like FNH but heterogeneous). AFP usually normal. Better prognosis than conventional HCC (5-year survival 30-50% vs 10-20%), more often resectable. DNAJB1-PRKACA fusion gene diagnostic. Reference: Honeyman JN. Science. 2014.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'The most common primary site of liver metastases is:',
'Lung', 'Colorectal cancer (via portal venous drainage)', 'Breast', 'Melanoma', 'Prostate',
'B', 'Liver metastases: most common malignant liver tumors. Primary colorectal cancer most common source (50% of CRC patients develop liver mets). Other sources: pancreatic, gastric, breast, lung, neuroendocrine tumors, melanoma, ocular melanoma. Portal venous drainage explains GI primary predilection. Liver-only colorectal mets potentially curable with resection (5-year survival 30-50%). Reference: Kopetz S. J Clin Oncol. 2009.',
'easy', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Criteria for resectability of colorectal liver metastases include:',
'Any number of metastases', 'Ability to achieve R0 resection, adequate future liver remnant (FLR), and no unresectable extrahepatic disease', 'Only single metastasis', 'Size <1cm only', 'No resection is ever indicated',
'B', 'Colorectal liver metastases resection criteria: (1) R0 resection achievable (complete resection with negative margins), (2) Adequate FLR - at least 20-30% normal liver or 40% cirrhotic (assess with volumetry), (3) No unresectable extrahepatic disease (or resectable/ablatable), (4) Patient fitness for major surgery. Number/size no longer absolute contraindications. Perioperative chemotherapy (FOLFOX). Portal vein embolization if FLR inadequate. 5-year survival 30-50%. Reference: Adams RB. Ann Surg. 2013.',
'hard', 'knowledge'),

-- Portal Hypertension (26-40)
('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Portal hypertension is defined as portal pressure gradient of:',
'<5 mmHg', '>5 mmHg (clinically significant if >10 mmHg)', '>30 mmHg', '5 mmHg exactly', '<2 mmHg',
'B', 'Portal hypertension: elevated portal venous pressure. Normal HVPG (hepatic venous pressure gradient) <5 mmHg. Definition: HVPG >5 mmHg. Clinically significant: HVPG >10 mmHg (risk of varices, decompensation). Causes: prehepatic (portal vein thrombosis), intrahepatic sinusoidal (cirrhosis - most common), intrahepatic presinusoidal (schistosomiasis), posthepatic (Budd-Chiari, cardiac). Reference: Garcia-Tsao G. Hepatology. 2017.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'The most common cause of portal hypertension worldwide is:',
'Portal vein thrombosis', 'Cirrhosis (intrahepatic sinusoidal)', 'Budd-Chiari syndrome', 'Heart failure', 'Schistosomiasis',
'B', 'Portal hypertension causes: Cirrhosis (80-90%) - intrahepatic sinusoidal, most common in developed world. Increased intrahepatic resistance (fibrosis, stellate cell contraction) + increased portal flow (splanchnic vasodilation). Schistosomiasis most common globally (presinusoidal). Prehepatic: portal/splenic vein thrombosis. Posthepatic: Budd-Chiari, cardiac causes. Reference: Garcia-Tsao G. Hepatology. 2017.',
'easy', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Clinical manifestations of portal hypertension include:',
'Only jaundice', 'Ascites, esophageal varices, splenomegaly, and portosystemic encephalopathy', 'Diarrhea only', 'Weight gain', 'Hypertension',
'B', 'Portal hypertension manifestations: (1) Ascites - most common complication of cirrhosis, (2) Esophagogastric varices - risk of bleeding (30% mortality per episode), (3) Splenomegaly (portal congestion), hypersplenism, (4) Portosystemic encephalopathy (shunting of ammonia past liver), (5) Caput medusae (periumbilical collaterals), (6) Hemorrhoids, (7) Hepatorenal syndrome, (8) Hepatopulmonary syndrome. Reference: Garcia-Tsao G. Hepatology. 2017.',
'easy', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Management of acute esophageal variceal bleeding includes:',
'Observation only', 'Resuscitation, IV octreotide, IV antibiotics, urgent upper endoscopy with band ligation', 'Immediate surgery', 'Oral medications only', 'CT scan first',
'B', 'Acute variceal bleed management: (1) Resuscitation - conservative transfusion (target Hb 7-8), avoid over-resuscitation (worsens portal pressure), (2) Vasoactive drugs - octreotide/somatostatin (splanchnic vasoconstriction, reduce portal pressure), (3) Prophylactic antibiotics (ceftriaxone - reduces infection, rebleeding, mortality), (4) Urgent EGD - within 12 hours, endoscopic band ligation (preferred) or sclerotherapy, (5) Airway protection (intubation if needed). Refractory: Balloon tamponade (Sengstaken-Blakemore, bridge to TIPS), TIPS. Reference: Garcia-Tsao G. Hepatology. 2017.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Transjugular intrahepatic portosystemic shunt (TIPS) creates:',
'External shunt', 'An intrahepatic connection between portal and hepatic veins, reducing portal pressure', 'Splenorenal shunt', 'Mesocaval shunt', 'Gastric bypass',
'B', 'TIPS: interventional radiology procedure. Stent creates connection between portal vein and hepatic vein through liver parenchyma. Effect: reduces portal pressure, decompresses varices. Indications: (1) Refractory/recurrent variceal bleeding, (2) Refractory ascites. Complications: hepatic encephalopathy (30-50% - porto-systemic shunting bypasses liver detoxification), TIPS stenosis/occlusion, increased cardiac preload (caution in heart failure), hemolysis. Reference: Boyer TD. Hepatology. 2010.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Primary prophylaxis for esophageal varices includes:',
'Surgery for all', 'Non-selective beta-blockers (propranolol, nadolol) or endoscopic band ligation', 'No prevention available', 'ACE inhibitors', 'Calcium channel blockers',
'B', 'Variceal bleeding prophylaxis: Primary (no prior bleed): (1) Non-selective beta-blockers (propranolol, nadolol, carvedilol) - reduce portal pressure, heart rate. Target: HR reduction 25% or to 55-60 bpm. (2) Endoscopic band ligation (EBL) - obliterates varices. Either option effective; EBL if contraindication to BB. Secondary prophylaxis (prior bleed): combination BB + EBL (reduces rebleeding 50% vs either alone). Screen high-risk cirrhotics with EGD. Reference: de Franchis R. J Hepatol. 2015.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Budd-Chiari syndrome is caused by:',
'Portal vein thrombosis', 'Hepatic vein outflow obstruction, often from thrombosis', 'Splenic vein thrombosis', 'Bile duct obstruction', 'Pancreatitis',
'B', 'Budd-Chiari syndrome: hepatic venous outflow obstruction (hepatic veins and/or IVC). Causes: hypercoagulable states (myeloproliferative disorders most common - polycythemia vera, factor V Leiden, antiphospholipid syndrome), malignancy, webs (Asia), pregnancy, OCPs. Presentation: hepatomegaly, ascites (high protein), abdominal pain, caudate lobe hypertrophy (spared - separate venous drainage). Diagnosis: Doppler US, CT, MRI, venography. Treatment: anticoagulation, TIPS, shunt surgery, liver transplant if decompensated. Reference: Valla DC. Gut. 2016.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Spontaneous bacterial peritonitis (SBP) in cirrhotic ascites:',
'Always has a clear source', 'Is diagnosed by ascitic fluid PMN count ≥250 cells/mm³ and treated empirically with ceftriaxone', 'Is treated with steroids', 'Requires surgery', 'Is always culture positive',
'B', 'SBP: infection of ascitic fluid without intra-abdominal surgical source. Mechanism: bacterial translocation from gut. Presentation: fever, abdominal pain, altered mental status, worsening ascites - but may be asymptomatic. Diagnosis: diagnostic paracentesis - PMN ≥250 cells/mm³ (presumptive diagnosis). Culture often negative. Treatment: empiric IV antibiotics (ceftriaxone or cefotaxime, broad gram-negative coverage), albumin (day 1 and 3 - reduces hepatorenal syndrome, mortality). Prophylaxis: norfloxacin for high-risk (prior SBP, GI bleed, low protein ascites). Reference: Runyon BA. Hepatology. 2013.',
'medium', 'knowledge'),

-- Hepatic Surgery and Bile Duct Injury (41-60)
('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'The Brisbane 2000 terminology for liver resection describes:',
'Only tumor removal', 'Standardized nomenclature for liver resections based on Couinaud segmental anatomy', 'Bile duct surgery', 'Transplant procedure', 'Biopsy technique',
'B', 'Brisbane 2000 terminology: standardized nomenclature for hepatic resection. Left hepatectomy: segments II-IV (to left of falciform). Right hepatectomy: segments V-VIII. Extended left: II-IV + V + VIII (± I). Extended right: IV-VIII (± I). Left lateral sectionectomy: II-III. Right anterior sectionectomy: V, VIII. Right posterior sectionectomy: VI, VII. Segmentectomy: single segment. Based on Couinaud anatomy, allows precise communication. Reference: Strasberg SM. HPB. 2000.',
'hard', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Future liver remnant (FLR) adequacy before major hepatectomy requires:',
'Any amount of liver', 'At least 20-30% for normal liver or 40% for chemotherapy-treated/cirrhotic liver', '>50% always', '>80%', '<10%',
'B', 'FLR assessment: critical for major hepatectomy. CT volumetry calculates FLR percentage. Requirements: (1) Normal liver: FLR ≥20-30%, (2) Chemotherapy-exposed/steatotic: ≥30%, (3) Cirrhotic: ≥40%. Inadequate FLR → post-hepatectomy liver failure (50% mortality). Options if inadequate: portal vein embolization (PVE) - induces FLR hypertrophy over 4-6 weeks, ALPPS (faster hypertrophy), staged hepatectomy. Reference: Vauthey JN. Ann Surg Oncol. 2000.',
'hard', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Portal vein embolization (PVE) before major hepatectomy:',
'Decreases liver function', 'Induces compensatory hypertrophy of the future liver remnant', 'Is not used', 'Causes liver failure', 'Shrinks the tumor',
'B', 'PVE: percutaneous embolization of portal vein branch(es) supplying segments to be resected. Effect: redirects portal flow to FLR → hypertrophy (20-40% increase over 3-6 weeks). Indication: marginal FLR where resection risky without hypertrophy. Performed 4-6 weeks before surgery. Tumor must not infiltrate portal vein. ALPPS (associating liver partition and portal vein ligation for staged hepatectomy): faster hypertrophy (1-2 weeks) but higher morbidity. Reference: Abulkhir A. Br J Surg. 2008.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Pringle maneuver during liver surgery involves:',
'Hepatic vein clamping', 'Temporary occlusion of the hepatoduodenal ligament (portal vein and hepatic artery) to control bleeding', 'Splenectomy', 'Bile duct division', 'Diaphragm repair',
'B', 'Pringle maneuver: temporary clamping of hepatoduodenal ligament (portal triad - portal vein, hepatic artery, bile duct). Effect: interrupts hepatic blood inflow, reduces bleeding during parenchymal transection. Technique: intermittent clamping (15-30 min cycles with 5 min reperfusion) to limit ischemia. Tolerated for 60-90 minutes total in normal liver. Does not control bleeding from hepatic veins. Reference: Gurusamy KS. Cochrane Database Syst Rev. 2007.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Bile duct injury during cholecystectomy most commonly involves:',
'Right hepatic duct only', 'Common bile duct (CBD) or common hepatic duct, often at the junction', 'Left hepatic duct', 'Cystic duct only', 'Intrahepatic ducts',
'B', 'Bile duct injury patterns (Strasberg classification): Type A - cystic duct stump leak or accessory duct. Type B - aberrant duct occlusion. Type C - aberrant duct leak. Type D - lateral CBD injury. Type E (Bismuth) - CHD/CBD transection/stricture. Most serious: misidentification of CBD as cystic duct → transection (Type E2-E4). Risk factors: acute inflammation, unclear anatomy, electrocautery injury. Prevention: Critical View of Safety. Incidence: 0.4-0.6% laparoscopic cholecystectomy. Reference: Strasberg SM. J Am Coll Surg. 1995.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'The Critical View of Safety during laparoscopic cholecystectomy requires:',
'Quick identification of cystic duct', 'Clear identification of two structures (cystic duct and cystic artery) entering the gallbladder after clearing the hepatocystic triangle', 'Immediate clip application', 'Intraoperative cholangiogram always', 'Division before visualization',
'B', 'Critical View of Safety (CVS): technique to prevent bile duct injury. Three criteria: (1) Hepatocystic triangle (Calot triangle) cleared of fat and fibrous tissue, (2) Lower third of gallbladder separated from liver (cystic plate), (3) ONLY two structures (cystic duct and cystic artery) seen entering gallbladder. If CVS not achievable: alternative approaches (fundus-first, subtotal cholecystectomy, open conversion, bailout procedure). Do not clip/cut unless CVS achieved or IOC performed. Reference: Strasberg SM. Am J Surg. 2010.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Management of bile duct injury recognized during cholecystectomy:',
'Ignore and close', 'If major injury, avoid attempted repair; place drain and refer to hepatobiliary specialist', 'Always repair immediately', 'Remove more bile duct', 'Never refer',
'B', 'Bile duct injury management: Timing of recognition critical. (1) Recognized intraoperatively - simple injuries may be repaired, major injuries: do NOT attempt primary repair (worsens outcome), place drain, get cholangiogram, REFER to specialized center. (2) Recognized postoperatively (days to weeks) - biloma drainage, ERCP/PTC for leak characterization. Definitive repair: Roux-en-Y hepaticojejunostomy (gold standard) performed 6-12 weeks later by experienced surgeon at referral center. Early referral improves outcomes. Reference: Stewart L. Ann Surg. 2014.',
'hard', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Cholangiocarcinoma is classified by location as:',
'Only one type', 'Intrahepatic (within liver), perihilar (Klatskin tumor at hilum), or distal (extrahepatic)', 'Always distal', 'Not classified by location', 'Never in liver',
'B', 'Cholangiocarcinoma classification: (1) Intrahepatic (10%) - arises from intrahepatic bile ducts, presents as liver mass, resection or transplant. (2) Perihilar/Klatskin (50-60%) - at hepatic duct confluence, most common type, Bismuth-Corlette classification. (3) Distal (20-30%) - involves distal CBD, presents like pancreatic head cancer (obstructive jaundice), Whipple procedure. Risk factors: PSC, liver flukes, biliary cysts. CA 19-9 often elevated. Reference: Razumilava N. Lancet. 2014.',
'medium', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Klatskin tumor (perihilar cholangiocarcinoma) is classified by the Bismuth-Corlette system based on:',
'Tumor size only', 'Extent of bile duct involvement at the hepatic confluence', 'Patient age', 'AFP level', 'Location in liver',
'B', 'Bismuth-Corlette classification (perihilar cholangiocarcinoma): Type I - below confluence (CHD). Type II - involves confluence but not left/right ducts. Type IIIa - extends into right hepatic duct. Type IIIb - extends into left hepatic duct. Type IV - involves both left and right hepatic ducts or multifocal. Guides resectability: Type I/II - bile duct resection ± hepatectomy. Type III - extended hepatectomy + bile duct resection. Type IV - often unresectable. Reference: Bismuth H. Ann Surg. 1975.',
'hard', 'knowledge'),

('c0000043-0000-0000-0000-000000000043', 'a0000003-0000-0000-0000-000000000003',
'Hydatid disease (echinococcosis) of the liver:',
'Is viral', 'Is caused by Echinococcus granulosus, forming cysts with characteristic imaging appearance', 'Only affects lungs', 'Has no treatment', 'Is always malignant',
'B', 'Hepatic hydatid disease: Echinococcus granulosus (dog tapeworm). Endemic areas: Mediterranean, Middle East, South America, Australia. Liver most common site (75%). Imaging: well-defined cyst, daughter cysts, calcified wall (pericyst), "water lily sign" (collapsed membranes). WHO classification guides treatment. Serologic testing (IgG ELISA). Treatment: albendazole (before and after intervention), PAIR (puncture, aspiration, injection of scolicidal, reaspiration), or surgical resection. Avoid rupture (anaphylaxis, dissemination). Reference: Brunetti E. Acta Trop. 2010.',
'medium', 'knowledge');

SELECT 'Surgery 3 MCQ Batch 28 (Hepatobiliary Disorders): 60 questions inserted' as status;
